Eli Lilly's basal insulin BIF has a hypoglycemic effect comparable to Novo Nordisk insulin

Compilenewborn

According to a phase 2 clinical trial (NCT03736785), a new once-a-week basal insulin injection has similar efficacy and safety compared with once-a-day basal insulin, and has a lower incidence of hypoglycemia.

The reduction in the number of weekly insulin injections may improve compliance with insulin therapy, which may be more effective than daily injections of basal insulin.

BIF (LY3209590) is a weekly basal insulin product under research by Eli Lilly and is developed for the treatment of diabetes, including type 1 diabetes and type 2 diabetes.

According to Lilly pipeline information, BIF is currently in phase II clinical development.

What was announced at the meeting was a 32-week phase II clinical trial with a total of 399 patients participating.

In the study, these patients were randomly assigned to one of three treatment groups: according to 2 different dosing algorithms (with different target values ​​for fasting blood glucose levels), once a week subcutaneous injection of BIF, or once a day subcutaneous injection of standard Degu insulin.

The results of the study showed that compared with patients treated with insulin degludec, patients treated with BIF achieved similar long-term blood sugar control, as shown by the results of the hemoglobin A1c measurement.

In addition, the use of BIF treatment can significantly reduce the incidence of hypoglycemia (<70mg/dL).

Severe, untreated hypoglycemia is a dangerous complication that can lead to seizures, loss of consciousness, and death.

Based on promising data, further studies have been initiated to evaluate the efficacy and safety of BIF in patients with type 1 diabetes (Phase II study, NCT04450407) and other groups of patients with type 2 diabetes (Phase II study, NCT04450394).

Reference source: Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin